L’immunothérapie dans le carcinome urothélial de la vessie : actualités thérapeutiques en 2023 (notice n° 125275)
[ vue normale ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 02156cam a2200301 4500500 |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20250112014707.0 |
| 041 ## - LANGUAGE CODE | |
| Language code of text/sound track or separate title | fre |
| 042 ## - AUTHENTICATION CODE | |
| Authentication code | dc |
| 100 10 - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Amaadour, Lamiae |
| Relator term | author |
| 245 00 - TITLE STATEMENT | |
| Title | L’immunothérapie dans le carcinome urothélial de la vessie : actualités thérapeutiques en 2023 |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. | |
| Date of publication, distribution, etc. | 2023.<br/> |
| 500 ## - GENERAL NOTE | |
| General note | 80 |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | Immunotherapy, notably immune checkpoint inhibitors, has recently inserted itself into the standard clinical dogma of bladder urothelial carcinoma, particularly as systemic therapy has seen minimal progress in the past 20 years. Since the initial approval of second-line immunotherapy in platinum refractory patients, new strategies have been evaluated to improve patient’s prognosis. We summarize in this review updated data regarding immunotherapeutic agents in bladder urothelial carcinoma. |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | L’immunothérapie, notamment les inhibiteurs des points de contrôle immunitaire, s’est récemment insérée dans l’arsenal thérapeutique du carcinome urothélial vésical – d’autant plus que le traitement systémique conventionnel a connu peu de progrès durant les 20 dernières années. Depuis l’approbation initiale de l’immunothérapie en deuxième intention chez les patients réfractaires aux platines, de nouvelles stratégies ont été développées afin d’améliorer le pronostic de ces patients. Nous résumons dans cette revue les avancées de l’immunothérapie dans le carcinome urothélial de la vessie. |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | carcinome urothélial |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | cancer de la vessie |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | inhibiteurs des points de contrôle immunitaire |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | bladder cancer |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | immune checkpoint blockade |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | urothelial carcinoma |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Nouiekh, Lamiae |
| Relator term | author |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Oualla, Karima |
| Relator term | author |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Benbrahim, Zineb |
| Relator term | author |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Arifi, Samia |
| Relator term | author |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Mellas, Nawfel |
| Relator term | author |
| 786 0# - DATA SOURCE ENTRY | |
| Note | Cahiers Santé Médecine Thérapeutique | 32 | 5 | 2023-09-01 | p. 223-231 | 2780-8858 |
| 856 41 - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | <a href="https://shs.cairn.info/revue-cahiers-sante-medecine-therapeutique-2023-5-page-223?lang=fr">https://shs.cairn.info/revue-cahiers-sante-medecine-therapeutique-2023-5-page-223?lang=fr</a> |
Pas d'exemplaire disponible.
Réseaux sociaux